PE20070319A1 - Formulaciones farmaceuticas de liberacion inmediata y con una carga de droga elevada de (4-ciclofenil) [4-(4-piridilmetil) ftalazin-1- ilo] no micronizado, y sus sales - Google Patents
Formulaciones farmaceuticas de liberacion inmediata y con una carga de droga elevada de (4-ciclofenil) [4-(4-piridilmetil) ftalazin-1- ilo] no micronizado, y sus salesInfo
- Publication number
- PE20070319A1 PE20070319A1 PE2006000619A PE2006000619A PE20070319A1 PE 20070319 A1 PE20070319 A1 PE 20070319A1 PE 2006000619 A PE2006000619 A PE 2006000619A PE 2006000619 A PE2006000619 A PE 2006000619A PE 20070319 A1 PE20070319 A1 PE 20070319A1
- Authority
- PE
- Peru
- Prior art keywords
- ilo
- micronized
- composition
- ftalazin
- cyclophenyl
- Prior art date
Links
- DGYIJVNZSDYBOE-UHFFFAOYSA-N [CH2]C1=CC=NC=C1 Chemical class [CH2]C1=CC=NC=C1 DGYIJVNZSDYBOE-UHFFFAOYSA-N 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229960002944 cyclofenil Drugs 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 3
- -1 SACROSE Substances 0.000 abstract 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 abstract 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 abstract 1
- XRUWKPASRHGRGE-UHFFFAOYSA-N 4-(4-chlorophenoxy)-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)OC1=CC=C(Cl)C=C1 XRUWKPASRHGRGE-UHFFFAOYSA-N 0.000 abstract 1
- 241000220479 Acacia Species 0.000 abstract 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 abstract 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 abstract 1
- 239000001828 Gelatine Substances 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 abstract 1
- 229930195725 Mannitol Natural products 0.000 abstract 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 abstract 1
- 239000004141 Sodium laurylsulphate Substances 0.000 abstract 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- GEAXLHPORCRESC-UHFFFAOYSA-N chlorocyclohexatriene Chemical class ClC1=CC=C=C[CH]1 GEAXLHPORCRESC-UHFFFAOYSA-N 0.000 abstract 1
- 239000007884 disintegrant Substances 0.000 abstract 1
- 239000000945 filler Substances 0.000 abstract 1
- 229920000159 gelatin Polymers 0.000 abstract 1
- 235000019322 gelatine Nutrition 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 235000001727 glucose Nutrition 0.000 abstract 1
- 235000010445 lecithin Nutrition 0.000 abstract 1
- 239000000787 lecithin Substances 0.000 abstract 1
- 229940067606 lecithin Drugs 0.000 abstract 1
- 239000000314 lubricant Substances 0.000 abstract 1
- 235000019359 magnesium stearate Nutrition 0.000 abstract 1
- 239000000594 mannitol Substances 0.000 abstract 1
- 235000010355 mannitol Nutrition 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
- 229940069328 povidone Drugs 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- OVSQVDMCBVZWGM-QSOFNFLRSA-N quercetin 3-O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-QSOFNFLRSA-N 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 abstract 1
- 229940079832 sodium starch glycolate Drugs 0.000 abstract 1
- 239000008109 sodium starch glycolate Substances 0.000 abstract 1
- 229920003109 sodium starch glycolate Polymers 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 239000000600 sorbitol Substances 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA SOLIDA QUE COMPRENDE A) UNA SAL DE (4-CLOROFENIL)[4-(4-PIRIDIL-METIL)-FTALAZIN-1-ILO] NO MICRONIZADO TAL COMO HIDROGENO SUCCINATO DE (4-CLOROFENIL)[4-(4-PIRIDIL-METIL)-FTALAZIN-1-IL]AMONIO QUE SE ENCUENTRA EN UNA CANTIDAD DE 50% A 95% EN PESO DE LA COMPOSICION Y SE LIBERA DE DICHA COMPOSICION EN 30 MINUTOS; Y B) EXCIPIENTES TALES COMO i) RELLENOS TAL COMO SACAROSA, SORBITOL, MANITOL, ENTRE OTROS; ii) AGLUTINANTES TAL COMO GLUCOSA, ACACIA, GELATINA, ENTRE OTROS; iii) AGENTES TENSIOACTIVOS TAL COMO LECITINA, ESTEARATO DE POLIOXIETILEN, LAURIL SULFATO DE SODIO, ENTRE OTROS; iv) DESINTEGRANTES TAL COMO CROSCARMELOSA SODICA, POVIDONA RETICULADA, GLICOLATO DE ALMIDON DE SODIO, ENTRE OTROS; Y v) DESLIZANTES Y LUBRICANTES TAL COMO ESTEARATO DE MAGNESIO, ESTEARATO DE CINC, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCESO DE PREPARACION. DICHA COMPOSICION ES UTIL PARA EL TRATAMIENTO DEL CANCER
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05090166A EP1731153A1 (en) | 2005-06-07 | 2005-06-07 | Immediate-release and high-drug-load pharmaceutical formulations of non-micronised (4-chlorophenyl)¬4-(4-pyridylmethyl)phthalazin-1-yl| and salts thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20070319A1 true PE20070319A1 (es) | 2007-04-12 |
Family
ID=34938467
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2006000619A PE20070319A1 (es) | 2005-06-07 | 2006-06-06 | Formulaciones farmaceuticas de liberacion inmediata y con una carga de droga elevada de (4-ciclofenil) [4-(4-piridilmetil) ftalazin-1- ilo] no micronizado, y sus sales |
Country Status (21)
| Country | Link |
|---|---|
| EP (2) | EP1731153A1 (es) |
| JP (1) | JP2008542420A (es) |
| KR (1) | KR20080031005A (es) |
| CN (1) | CN101242840A (es) |
| AR (1) | AR053889A1 (es) |
| AU (1) | AU2006256852A1 (es) |
| BR (1) | BRPI0613393A2 (es) |
| CA (1) | CA2610975A1 (es) |
| CR (1) | CR9563A (es) |
| DO (1) | DOP2006000127A (es) |
| EC (1) | ECSP078038A (es) |
| GT (1) | GT200600242A (es) |
| IL (1) | IL187905A0 (es) |
| MX (1) | MX2007015494A (es) |
| NO (1) | NO20080065L (es) |
| PE (1) | PE20070319A1 (es) |
| RU (1) | RU2007147951A (es) |
| TW (1) | TW200716115A (es) |
| UY (1) | UY29582A1 (es) |
| WO (1) | WO2006131393A1 (es) |
| ZA (1) | ZA200800112B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1958616A1 (en) * | 2007-02-13 | 2008-08-20 | Bayer Schering Pharma Aktiengesellschaft | Pharmaceutical formulations of 1-[4-chloroanilino]-4-[4-pyridylmethyl] phthalazine or salts thereof |
| TW201618783A (zh) | 2014-08-07 | 2016-06-01 | 艾森塔製藥公司 | 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CO4950519A1 (es) * | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
-
2005
- 2005-06-07 EP EP05090166A patent/EP1731153A1/en not_active Withdrawn
-
2006
- 2006-06-06 KR KR1020087000236A patent/KR20080031005A/ko not_active Withdrawn
- 2006-06-06 GT GT200600242A patent/GT200600242A/es unknown
- 2006-06-06 MX MX2007015494A patent/MX2007015494A/es not_active Application Discontinuation
- 2006-06-06 JP JP2008515151A patent/JP2008542420A/ja active Pending
- 2006-06-06 EP EP06762010A patent/EP1888072A1/en not_active Withdrawn
- 2006-06-06 CN CNA2006800294742A patent/CN101242840A/zh active Pending
- 2006-06-06 WO PCT/EP2006/005600 patent/WO2006131393A1/en not_active Ceased
- 2006-06-06 PE PE2006000619A patent/PE20070319A1/es not_active Application Discontinuation
- 2006-06-06 CA CA002610975A patent/CA2610975A1/en not_active Abandoned
- 2006-06-06 BR BRPI0613393-2A patent/BRPI0613393A2/pt not_active IP Right Cessation
- 2006-06-06 RU RU2007147951/15A patent/RU2007147951A/ru not_active Application Discontinuation
- 2006-06-06 AU AU2006256852A patent/AU2006256852A1/en not_active Abandoned
- 2006-06-06 TW TW095120062A patent/TW200716115A/zh unknown
- 2006-06-07 UY UY29582A patent/UY29582A1/es not_active Application Discontinuation
- 2006-06-07 DO DO2006000127A patent/DOP2006000127A/es unknown
- 2006-06-07 AR ARP060102363A patent/AR053889A1/es unknown
-
2007
- 2007-12-05 IL IL187905A patent/IL187905A0/en unknown
- 2007-12-06 CR CR9563A patent/CR9563A/es not_active Application Discontinuation
- 2007-12-19 EC EC2007008038A patent/ECSP078038A/es unknown
-
2008
- 2008-01-04 ZA ZA200800112A patent/ZA200800112B/xx unknown
- 2008-01-04 NO NO20080065A patent/NO20080065L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1888072A1 (en) | 2008-02-20 |
| ECSP078038A (es) | 2008-01-23 |
| CN101242840A (zh) | 2008-08-13 |
| IL187905A0 (en) | 2008-03-20 |
| WO2006131393A1 (en) | 2006-12-14 |
| MX2007015494A (es) | 2008-02-22 |
| KR20080031005A (ko) | 2008-04-07 |
| EP1731153A1 (en) | 2006-12-13 |
| CA2610975A1 (en) | 2006-12-14 |
| DOP2006000127A (es) | 2006-12-15 |
| AU2006256852A8 (en) | 2006-12-14 |
| JP2008542420A (ja) | 2008-11-27 |
| RU2007147951A (ru) | 2009-07-20 |
| AR053889A1 (es) | 2007-05-23 |
| CR9563A (es) | 2008-02-20 |
| TW200716115A (en) | 2007-05-01 |
| ZA200800112B (en) | 2010-06-30 |
| BRPI0613393A2 (pt) | 2011-01-11 |
| UY29582A1 (es) | 2007-01-31 |
| GT200600242A (es) | 2007-02-09 |
| NO20080065L (no) | 2008-03-06 |
| AU2006256852A1 (en) | 2006-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20061345A1 (es) | Composicion farmaceutica que comprende sorafenib | |
| PE20120626A1 (es) | Composiciones farmaceuticas que comprende nilotinib | |
| PE20100252A1 (es) | Nuevas formulaciones farmaceuticas solidas que comprenden dimaleato de 4-[(3-cloro-4-fluorofenil) amino]-6-{[4-(n,n-dimetilamino)-1-oxo-2-buten-1-il] amino}-7-((s)-tetrahidrofuran-3-iloxi)-quinazolina | |
| PE20090015A1 (es) | Preparacion solida | |
| PE20060505A1 (es) | Composicion farmaceutica de metilamida del acido 4{4-[3-(4-cloro-3-trifluorometilfenil)-ureido]-3-fluoro-fenoxi}-piridin-2-carboxilico en la forma de una dispersion solida util en trastornos hiperproliferativos | |
| CU20100200A7 (es) | Una composición farmacéutica que comprende n-(3,4-difluoro-2-4-iodofenilamino)-6-metoxifenil)-l-(2,3-dihidroxipropil)ciclopropano-l-sulfonamida, útil para el tratamiento y prevención del cáncer y de enfermedades inflamatorias | |
| CO6150163A2 (es) | Composiciones adecuadas para administracion oral que comprende un derivado de triazolo [4,5-d] pirimidina | |
| NZ593848A (en) | Synthesis of 18f-radiolabeled styrylpyridines from tosylate precursors and stable pharmaceutical compositions thereof | |
| PE20081150A1 (es) | Inhibidores de dipetidilpeptidasa | |
| AR072755A2 (es) | Comprimido de carga de droga alta del compuesto 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil]-benzamida | |
| PE20141855A1 (es) | Benzotienilo-pirrolotriazinas disustituidas y sus usos | |
| PE20142318A1 (es) | Formulaciones de (+)-2-[1-(3-etoxi-4-metoxi-fenil)-2-metansulfonil-etil]-4-acetilaminoisoindolin-1,3-diona | |
| CL2016000816A1 (es) | Forma de dosificación que comprende al compuesto (s)-3-(4-((4-morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona, una cantidad de 90 hasta 99,9 por ciento en peso del peso total de una mezcla de almidón y lactosa como portador o excipiente, y acido esteárico como lubricante; su uso en el tratamiento de cáncer y enfermedades autoinmunes, entre otras. | |
| CR9875A (es) | Inhibidores de dipeptidilo peptidasa para tratar diabetes | |
| CR9721A (es) | Compuestos de carbamato para utilizar en el tratamiento de desordenes neurodegenerativos | |
| PE20160947A1 (es) | Composicion farmaceutica oral que comprende acido 3-[5-(2-fluorofenil)-[1,2,4]oxadiazol-3-il]benzoico | |
| PE20090895A1 (es) | Derivados de triazol como inhibidores de la jak quinasa | |
| ECSP088974A (es) | Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3) | |
| PE20120476A1 (es) | Composiciones farmaceuticas estabilizadas que comprenden fesoterodina | |
| BR112013032122A2 (pt) | liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos | |
| CO6612226A2 (es) | Tableta | |
| TNSN07447A1 (en) | Treatment of liver diseases in which iron plays a role in pathogenesis | |
| ECSP10010428A (es) | Derivados de indazol | |
| HRP20120085T1 (hr) | Pripravak zibotentana koji sadrži manitol i mikrokristalnu celulozu | |
| PE20090371A1 (es) | Formulacion de nevirapina de liberacion prolongada |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |